Adriano M. Pellicelli, Cecilia DAmbrosio, Maria L. Dessanti, Roberto Villani, Lucia Fondacaro, Lucia Miglioresi, Lucia R. Grillo, Arnaldo Andreoli
Rituximab is a chimeric anti-CD20 monoclonal antibody that is a widely used for the treatment of B cells non-Hodgkin lymphoma. The use of chemotherapy regimens containing rituximab in HCV-positive patients with non-Hodgkin lymphoma has been associated with liver dysfunction, but no cases of cholestatic hepatitis C were described. To our knowledge, this is the first case of cholestatic hepatitis C in an HCV-positive patient with diffuse large B-cell lymphoma describes in the literature. We discuss the pathogenetic mechanisms underlying this severe form of hepatitis and describe its evolution after antiviral treatment.
Key words. HCV., NHL., Liver damage., HCVRNA., Immunosuppression.